

SOCS1/SOCS3 Immune Axis Modulates Synthetic Perturbations in IL6 Biological Circuit for Dynamical Cellular Response

Bhavnita Soni¹ and Shailza Singh^{1*}

¹ National Centre for Cell Science, NCCS Complex, Ganeshkhind, SPPU, Pune-411007, India

Abstract:

Macrophage phenotype plays a crucial role in the pathogenesis of Leishmanial infection. Pro-inflammatory cytokines are the key regulators that eliminate the infection induced by Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway. Suppressor of cytokine signaling (SOCS) is a well-known negative feedback regulator of JAK/STAT pathway. However, change in expression levels of SOCS in correlation with the establishment of infection is not well understood. Mathematical modeling of IL6 signaling pathway have helped identified the role of SOCS1 in establishment of infection. Furthermore, the ratio of SOCS1 and SOCS3 has been quantified both *in silico* as well as *in vitro*, indicating an immune axis which governs the macrophage phenotype during *L. major* infection. The ability of SOCS1 protein to inhibit the JAK/STAT1 signaling pathway and thereby decreasing pro-inflammatory cytokine expression makes it a strong candidate for therapeutic intervention. Using synthetic biology approaches, peptide based immuno-regulatory circuit have been designed to target the activity of SOCS1 which can restore pro-inflammatory cytokine expression during infection.

*Corresponding author

Email: shailza_iitd@yahoo.com, singhs@nccs.res.in

Phone: +91-20-25708296/95

Fax: +91-20-25692259

| S.No. | Abbreviations | |
|-------|-------------------------------|---|
| 1. | AIF | Anti-inflammatory factor |
| 2. | CMV | Cytomegalovirus |
| 3. | CT | Comparative threshold |
| 4. | CTI | Control + Transfected + Infected |
| 5. | CTIM | Control + Transfected + Infected + Miltefosine |
| 6. | DAPI | 4',6-diamidino-2-phenylindole |
| 7. | DMEM | Dulbecco's Modified Eagle Medium |
| 8. | DSM | Diseased State Model |
| 9. | EDTA | Ethylenediaminetetraacetic acid |
| 10. | EV | Empty Vector |
| 11. | GFP | Green Fluorescent Protein |
| 12. | HSM | Healthy State Model |
| 13. | IFNγ | Interferon gamma |
| 14. | IPTG | Isopropyl β - d-1-thiogalactopyranoside |
| 15. | iGEM | International Genetically Engineered Machine |
| 16. | iNOS | Inducible nitric oxide synthase |
| 17. | IL6 | Interleukin 6 |
| 18. | IL1β | Interleukin 1 beta |
| 19. | IL10 | Interleukin 10 |
| 20. | JAK/STAT | Janus kinase/signal transducer and activator of transcription |
| 21. | LACR | Lactose Repressor |
| 22. | LPS | Lipopolysaccharide |
| 23. | MOGA | Multi-objective genetic algorithm |
| 24. | ODE | Ordinary differential equation |
| 25. | PBC | Periodic boundary condition |
| 26. | PCA | Principal component analysis |
| 27. | PFA | Paraformaldehyde |
| 28. | PGN-SA | Peptidoglycan from <i>Staphylococcus aureus</i> |
| 29. | PEI | Polyethylenimine |
| 30. | RPMI | Roswell Park Memorial Institute |
| 31. | RMSD | Root-mean-square deviation |
| 32. | RMSF | Root mean square fluctuation |
| 33. | SH2 | Src Homology 2 |
| 34. | SOCS | Suppressor Of Cytokine Signaling |
| 35. | TIP3P | Transferable intermolecular potential with 3-point |
| 36. | TLR | Toll like Receptors |

36

37

38 INTRODUCTION:

39 Suppressor of cytokine signaling (SOCS) is known for negative feedback regulation of Janus
40 kinase/signal transducer and activator of transcription (JAK/STAT) pathway(1). In various
41 infectious disease, SOCS regulates the activation of cell by pro-inflammatory cytokines (2). Post
42 natal death of SOCS1 knockdown mice have been reported within three weeks due to IFN- γ -
43 induced hyper-inflammation (3). Contrary to this, there are few infectious diseases wherein
44 parasite inhibits activation of immune cells through selective expression of few SOCS (4). One
45 such example is Leishmaniasis wherein expression of SOCS isoforms plays a crucial role in the
46 establishment of infection (5).

47 We all know the immune system is a tremendously complex system which needs to be
48 understood through mathematical models of varied and myriad number of interconnecting
49 components. Intuitively, systems biologists talk in two scenarios wherein one focuses on
50 intracellular molecular networks involved in gene regulation, signaling and the other molecular
51 processes while the other focuses on systemic aspects of immune system dynamics. Using
52 systems biology approaches, we have already established mathematically, the role of
53 SOCS1/SOCS3 ratio in raising the immune response during early stage of *L. major* infection (6)
54 (BIOMD0000000873). We observed the ratio to be >1 , which depicts that an incremental
55 increase in concentration of SOCS1 eventually shuts down the pathways responsible for its pro
56 inflammatory behavior. One of the key strength of this approach is that it allows simultaneous
57 validation of the observations obtained from mathematical modeling and mimics *in vitro/in vivo*
58 systems. To commensurate this, modeling and simulations are integral part of systems biology,
59 where in, mathematical modeling guides' *in vitro/ in vivo* experimentation which further aid in
60 model refinement leading to better understanding of complex biological systems. Thus, model
61 refinement is an important step toward unfolding the crucial dynamics of complex biological
62 systems (7). It would be worthwhile to mention here that performing *in silico* deterministic
63 simulation has much more advantage than the stochastic one. In deterministic model, a given
64 choice of parameters and initial conditions always lead to the same set of model predictions,
65 models of this sort typically are in the form of coupled ODEs describing the dynamics of
66 molecular concentrations as most appropriate. However, investigation of a stochastic model is
67 complicated by the fact that system trajectories varies from realization to realization and solving

68 the master equation becomes little more complex due to the combinatorial explosion of the
69 parameter and configuration space(8). In corroboration to this, based on literature evidences we
70 have constructed comprehensive signaling network of cytokine IL-6. We know IL6 involvement
71 in a multitude of processes right from immune response to pathogens to cancer related processes
72 and also in the regulation of inflammatory processes linked to insulin resistance(9, 10, 11).
73 Analysis of the network suggests several model modifications in order to better fit available
74 knowledge and data, which further helped intrigued our experimental hypothesis to be pursued.
75 Thus, in the present work, using experimental observations we have refined our previous models
76 of Healthy state model (HSM) and Diseased state model (DSM) established during early stage of
77 *Leishmania major* infection. HSM referring to M1 and DSM refers to M2 phenotype of
78 macrophage respectively during infection.

79 Later the refined models were used to design therapeutics based on synthetic biology approaches
80 using biological components (promoter, RBS, RNA polymerase, spacer etc.) that have been
81 rewired to act as a transcriptional pool. Each biological entity represents one transcription unit.
82 Extensive work has been done using tunable synthetic circuit in mammalian cell for therapeutic
83 purpose such as the use of gene circuit for sensing and suppressing inflammation (12), treatment
84 of metabolic syndrome (13), for anti- cancerous gene therapy (14) and the use of synthetic gene
85 circuit for immune mediated therapy (15). Besides these, synthetic mammalian gene circuit has
86 also been used to deliver specific RNA to cell (16). The success of the mammalian based
87 synthetic gene regulatory circuit in various diseases has drawn our attention and motivated us to
88 generate a potent novel therapeutics in Leishmaniasis. Here, in this paper, we have assimilated
89 different parts of the transcriptional unit (promoter, RBS, RNA polymerase, spacer etc.), pooled
90 from genetic pool to generate a functionally active synthetic circuit. The design is precise
91 keeping it modular in fashion which ensures the simple and reproducible workability of the
92 circuit for lest it should not be visualised as Rube Goldberg machine. To the best of our
93 knowledge, this manuscript serves as the first ever report of IL6 based synthetic gene regulatory
94 circuit for treating *L. major* infection at cellular level.

95 There are various forms of synthetic devices used for therapeutic purpose, more complex types
96 are oscillators and toggle switches which contains two or more stable states with or without an
97 intermediate unstable states (17). The simpler form of synthetic device is the repressilator,

98 characterized by the presence of feedback loop with at least three genes out of which one encode
99 for protein that represses the next gene in loop (18). In the present study, we have used the
100 combination of toggle switch and repressilator to design the synthetic circuit that may tweak the
101 immune response from Th2 to Th1 type during early stage of leishmanial infection. The immuno
102 based synthetic device serves as the first attempt to revert the anti-inflammatory action of IL6
103 into its pro-inflammatory behavior through mathematically established SOCS1/SOCS3 immune
104 axis. Thus, the increasing body of vast knowledge together with comprehensive mathematical
105 analysis may aid immuno-based synthetic device to become a reality in Leishmania infection
106 model system (Fig.1).

107

108 **RESULTS:**

109 **A. SOCS1/SOCS3 differential expression governing macrophage polarization**

110 Interleukin 6 cytokine is one of the major cytokine which is released during interaction of
111 LPG (Lipophosphoglycan) with TLR2 at an early stage of infection (19). Previously, we
112 have generated two models deciphering the dual action of IL6 in Leishmaniasis i.e. DSM
113 depicting the anti-inflammatory role and HSM showing pro inflammatory role of IL6 (6)
114 We have hypothesized that IL6 may act as an anti- inflammatory cytokine causing
115 selective expression of SOCS proteins resulting in converting the macrophage in M2
116 phenotype during Leishmanial infection. In this process, first the amount of IL6 is
117 quantified during post one hour of *L. major* infection (Fig.2g) and as per our previous
118 observation, 100 time unit simulation of the diseased state model shows differential
119 expression of SOCS1 and SOCS3 protein (6). This crucial finding was further validated
120 in *in vitro* by infecting the macrophages with *L. major* stationary phase promastigotes in
121 the presence of Interleukin 6 cytokine. Western blot data depicted increased expression of
122 SOCS1 and SOCS3 protein during infection which further got enhanced in presence of
123 IL6 treatment. Densitometric analysis identifies the ratio of SOCS1/SOCS3 as 3:2 post
124 one hour of infection (Fig.2e and 2f). The obtained data signifies the anti- inflammatory
125 role of IL6 in establishing SOCS1/SOCS3 immune axis during early stage of infection.

126

127 The IL6 mathematical model is constructed for it to be testable through further
128 experimentation. We need to quantify the uncertainty of those predictions, given the
129 information they are built upon. Either the local analysis of sensitivities or the non-local
130 sampling of parameter space can be used to estimate prediction uncertainties. Model re-
131 parameterizations and targeted experiments can result in identifiable parameters. Here, in
132 this paper what we have seen is that even though some parameter in the ensemble vary
133 considerably, the ensemble of trajectories shows much less variation. Nonetheless, the
134 reality is that many mathematical models are published with parameters that do not
135 systematically fit to the data. We would like to reiterate that our previously published IL6
136 model (BIOMD0000000873) does not fit the experimental data leading us to only use the
137 synthetic data generated by the model itself. Counter intuitively, we went ahead in
138 understanding the sensitivity of model predictions to parameters which would suggest
139 possible perturbations of interest and adopted the established protocol of our lab.
140 On the basis of aforementioned strategies, refinement of the mathematical models i.e.
141 Diseased state (M2 phenotype); DSM and Healthy state (M1 phenotype); HSM have been
142 performed. Each model contained 46 species comprising of 41 reactions in DSM and 40
143 reactions in HSM respectively (S1). After a simulation for 100 time unit, DSM shows
144 increased concentration of Anti-inflammatory factors (AIF) as well as SOCS1 protein
145 whereas HSM shows higher concentration of iNOS and SOCS3 (Fig. 2a and 2b). The
146 model has been submitted to BioModel database with ID MODEL2005140001. Later,
147 both the models were subjected to Sensitivity and Principal component analysis followed
148 by flux analysis. In this case, the PCA approach was laid down to identify multivariate
149 relationship between IL6 signaling events and also link them to *in vitro* cellular
150 phenotypes. We adopted the gold standard method of PCA and mathematical modeling
151 approaches to more accurately differentiate between disease progressions states (Fig 2d).
152 These multivariate analyses led us to churn out the major reactions that adds to disease
153 progression at cellular level (Table1), followed by the Ordinary differential equation of
154 (ODEs) of major biochemical reaction.

155

$$1. \frac{d([\text{TLR2/6-LPG}] \cdot V_{\text{membrane}})}{dt} = +V_{\text{membrane}} \cdot \left(8e - 09 \cdot [\text{TLR2}] \cdot \left[\frac{\text{TLR6}}{1} \right] \cdot V_{\text{membrane}} \cdot [\text{LPG}] \cdot V_{\text{membrane}} \right) - (0.23 \cdot [\text{"TLR2/6 - LPG"}] \cdot V_{\text{membrane}})$$

156

$$157 \quad 2. \frac{d([\text{MyD88}] \cdot V_{\text{cytosol}})}{dt} = -V_{\text{cytosol}} \left(\frac{15 \cdot [\text{MyD88}]}{1 + [\text{MyD88}] \cdot V_{\text{CYTOSOL}}} \right) + (0.23 \cdot [\text{"TLR2/6 - LPG"}] \cdot V_{\text{membrane}})$$

158

$$159 \quad 3. \frac{d([\text{STAT3.P}] \cdot V_{\text{CYTOSOL}})}{dt} = -V_{\text{CYTOSOL}} \cdot (0.05 \cdot [\text{STAT3.P}]) + V_{\text{CYTOSOL}} \cdot \left(\frac{15 \cdot [\text{STAT3}\{\text{CYTOSOL}\}]}{1 + [\text{STAT3}\{\text{CYTOSOL}\}] \cdot V_{\text{CYTOSOL}}} \right) + V_{\text{CYTOSOL}} \left(\frac{1000 \cdot [\text{STAT3}\{\text{CYTOSOL}\}]}{5000 + [\text{STAT3}\{\text{CYTOSOL}\}] \cdot V_{\text{CYTOSOL}}} \right)$$

161

$$162 \quad 4. \frac{d([\text{SOCS3}\{\text{CYTOSOL}\}] \cdot V_{\text{CYTOSOL}})}{dt} = +(0.5 \cdot [\text{SOCS3}\{\text{NUCLEUS}\}] \cdot V_{\text{NUCLEUS}})$$

$$163 \quad 5. \frac{d([\text{SOCS1}\{\text{CYTOSOL}\}] \cdot V_{\text{CYTOSOL}})}{dt} = +(0.3 \cdot [\text{SOCS1}\{\text{NUCLEUS}\}] \cdot V_{\text{NUCLEUS}})$$

164

165 **B. Systems study reveals phosphorylated STAT1 and STAT3 as cross talk**

166

167 At the intracellular level, model captures a variety of signaling events, most important
 168 being the signal transduction networks emanating from receptors and engaging
 169 downstream in crosstalk. With respect to our previous observation (6) and now in refined
 170 models as well, cytoplasmic phosphorylated STAT1 and STAT3 are found to be as cross
 171 talk points between TLR2/TLR6-IL6 signaling pathway, later validated through western
 172 blotting. We observed that, in both the cases, the activation of either of the two pathways
 173 represents phosphorylation of STAT1 and STAT3, and is inhibited with the addition of
 174 respective inhibitor (Fig 3c, 3d). Each pathway is then further activated in presence of
 175 their respective inhibitors signifying constant phosphorylation of both the STATs (Fig
 176 3b). This shows phosphorylated STAT1 and STAT3 acts as a cross talk point between
 177 IL6 and TLR2 signaling pathway (S7).

177

178 C. **Multi objective optimization of mathematical model:** The idea of performing multi-
179 objective optimization of mathematical model is to elucidate how network is evolvable
180 with respect to changing environmental condition. The evolved network could be a better
181 platform to generate any kind of therapeutics. *Leishmania* interferes with the IL6
182 signaling network by modulation of SOCS1:SOCS3 ratio. SOCS1 is responsible for anti-
183 inflammatory behavior and SOCS3 corresponds to pro inflammatory behavior. Once the
184 rewiring of the network is completed, the network should evolve towards pro
185 inflammatory phenotype. Since obtaining evolvability of a system is a multi-optimization
186 problem, we opted for Multi-objective genetic algorithm (MOGA) and defined objective
187 function as :

188 function $y = \text{SOCS}(x)$
189 $y(1) = -((\exp(1*x(1)) + \text{abs}(1*x(2)) + 2*x(3) + \text{abs}(2*x(4))))^3$; Pro-inflammatory
190 $y(2) = ((\exp(2*x(1)) + \text{abs}(2*x(2)) + 1*x(3) + \text{abs}(1*x(4))))^2$; Anti-inflammatory
191 end

192
193
194 The decision variables embedded in $y(1)$ and $y(2)$ objective functions are cytokines,
195 whose expression levels would be measured in *in vitro* experiments. They are denoted as
196 x_1 , x_2 , x_3 and x_4 , representing the cytokines IL-10, TGF β , TNF- α and IFN- γ
197 respectively. It shows that x_1 and x_2 decision variables represent the anti-inflammatory
198 cytokines for the fitness function of SOCS1 protein ($y(1)$). Similarly, x_3 and x_4
199 represents (pro-inflammatory) fitness function of SOCS3 protein. When genetic
200 algorithm is performed with defined objective functions, a graph of individual v/s
201 generation is obtained showing elite population (Fig 4a), this signifies the importance of
202 SOCS1: SOCS3 ratio, as a character of elite population. The average distance between
203 the individual is low throughout the run, indicate decreased mutation rate or
204 conservedness of the ratio throughout many generations (Fig 4b). The Pareto front
205 obtained for the opposing objective functions have more than 30 non-dominated solutions
206 that are not discontinuous and the average spread measure for these solutions is 0.167776
207 (Fig 4c & 4d). The Pareto optimality obtained using genetic algorithm states that during

208 the process of natural selection the ratio of SOCS1: SOCS3 obtained through
209 mathematical modeling analysis (Fig.2) together with the anti and pro inflammatory
210 cytokine is selected (conserved) and passed onto next generation as an elite character. By
211 targeting this conserved ratio, the designed therapeutics would be more effective for
212 generations turning the macrophage polarization towards M1 phenotype.

213 Evolutionary algorithms iteratively improve circuit performance by randomly mutating
214 parameters across a population of circuits, and retaining circuits with the highest fitness
215 and selectivity. This approach generates functioning circuits with fewer computations
216 and has an added advantage of providing some insight into how gene circuits might
217 evolve during natural selection. The final output of our algorithm is a simplified gene
218 network that defines a dynamical system whose response is a switch-like function of its
219 inputs with the anti-inflammatory response getting shifted towards pro-inflammatory
220 response.

221

222 **D. SOCS1 as a target for therapeutic intervention**

223 By performing the process of model reduction, there are various other reactions which
224 have been filtered out in both the models (Table1). One of the major reaction with high
225 flux during analysis was the formation of active cytoplasmic SOCS1 protein (SOCS1
226 {NUCLEUS} -> SOCS1 {CYTOSOL}) in DSM. Cytoplasmic SOCS1 was among the
227 major nodes identified through principle component analysis and also showed high
228 sensitivity score (Fig 1). Thus, cytoplasmic SOCS1 is selected as a target for further
229 therapeutic intervention.

230

231 **E. Peptide Design, Docking and MD simulation of Selected Complex**

232 We designed a small peptide library of 15 peptides based on Machine Learning (**S2A**),
233 assumption was on the non-conserved region in SOCS1 protein. Peptide 8
234 (NSQKADDLVDNNVI) was selected on the basis of number of interacting residues as
235 well as low energy complex forming ability (**S2B**). The SOCS1-Peptide8 complex was
236 then subjected to 30ns MD simulation. The RMSD plot shows that the complex got

237 stabilized post 20 ns and the complex achieved its minimum energy state conformation
238 (Fig.5f). (S3).

239

240 **F. Systems driven synthetic biological circuit design**

241 For synthetic circuits, one can emulate natural designs and/or use intuition and
242 mathematical modeling to guide network choice. In both the cases, these approaches start
243 from a single network – either based on some understanding of the mechanism, or on
244 some intuition of the researcher. For addressing the present issue, we have designed
245 mammalian tunable synthetic repressilator. The designed system contains *LacI*, *peptide 8*,
246 *gfp* genes arranged in modular fashion under the influence of CMV promoter (S4). IL6
247 synthetic gene circuit is constructed by assembling all necessary parts and pools. Parts are
248 well defined DNA sequences having function in transcription or translation, whereas
249 pools are the abstract places where free molecules of signal carriers are stored. Parts are
250 composed into higher modules, the transcription units that interact by exchanging
251 molecules of signal carriers such as transcription factor and small RNAs. Thus, in a
252 circuit scheme, pools of signal carriers are the graphical interfaces among transcription
253 units. It is worth noticing that the content of any pool plays a non-negligible role in
254 determining the circuit dynamics. Parts and pools are modeled independently according
255 to mass action kinetics by exchanging fluxes of signal carriers. These fluxes furthermore
256 determine input/output in the genetic circuit and influence circuit performance. Parts that
257 host interactions with signal carriers such as the promoter that binds RNA polymerase
258 have access to the value of the concentration of free signal carrier molecules into their
259 corresponding pools. The system is auto negative regulatory in nature due to the presence
260 of Lac repressor gene (*LacI*) and its function is inhibited by IPTG (Fig6a). In absence of
261 IPTG the system remains turn off (OFF STAGE) signifies no production of GFP (green
262 fluorescent protein) and peptide 8, whereas in presence of IPTG the system is in ON
263 STAGE representing the production of GFP and peptide 8 (Fig 6f). Both the stages have
264 been confirmed through BoolNet package and transfected successfully in macrophage
265 derived cell line (Fig 6h and 6i) (S5). The simulation have been performed for 100 time
266 units with graph representing oscillatory behavior confirming the auto negative

267 regulatory nature of the designed system. The wiring graph obtained, shows that Lac
268 repressor is the center/master for regulation of the whole system (Fig 6e). Using its time
269 series data, convergence of statistical variables have been obtained, signifying modularity
270 as well as orthogonality (Fig 6d). The null-cline point obtained through ODE solver states
271 that the system has one stable state at a given time point, system will either be in an ON
272 state or in OFF stage (Fig 6d). The results further imply that the system has tendency to
273 follow same trajectory even in presence of external perturbations, known as canalization.
274 *In silico* method to study circuit canalization is very similar to sensitivity analysis.

275

276 ***In vitro* validation**

277 **A. Cytokine profiling:**

278 To determine the efficacy of designed synthetic circuit, cytokine profiling for various groups
279 were performed using Taqman chemistry. Miltefosine is taken as positive control and the study
280 was divided into five groups namely Control (C), Infection(I), Empty Vector (EV), Transfection
281 + Infection (CTI), Transfection + Infection + Miltefosine (CTIM).

282

283 During the initial interaction, cytokines having pro- inflammatory behavior are found to increase
284 with the introduction and expression of synthetic circuit. The expression was further increased
285 with the treatment of Miltefosine. If we quickly observe the cytokine profiling of the infectious
286 state, TNF α shows a constant 2-3 fold change which symbolizes its role in parasite clearance
287 during initial infection but the fold change of IL12 (2-5 fold change) is low as compared to fold
288 change of IL10 (7-8 fold change). This predominantly shows the negative regulation of IL10 over
289 IL12 which turns the polarization of macrophages towards M2 phenotype (Fig 6). Further adding
290 to this, there was no expression of IFN γ and iNOS which is due to the constant increase in fold
291 change of TGF β (0-45 minute post infection), depicts that TGF β is strong anti- inflammatory
292 cytokine which suppresses the expression of IFN γ and iNOS (Fig 7b & 7c). IL1 β has both pro
293 and anti-inflammatory action, the increase in fold change of IL1 β in synchrony with IL10 and
294 TGF β shows its predominant anti-inflammatory action in establishing infection during early
295 state (Fig 7a & 7c). There was no expression of IL4 observed post one hour of infection.

296 On introduction of designed synthetic circuit in infected cell, there is rapid increase of TNF α
297 which has been observed with nearly 10 fold change (60 minutes post infection) and which
298 further increase with Miltefosine treatment (Fig 7a). This proves that the designed circuit
299 promotes the levels of TNF α in micro- environment establishing the anti- leishmanial response
300 during early stage of infection. Furthermore, sharp fall in fold change of IL10 and TGF β have
301 been observed. The fold change levels of IL10 have reached to 1-3 times from 7-8 times whereas
302 the fold change of TGF β has been dropped from 4-5 times to 1-2 times (Fig 7c) representing the
303 negative regulation of TNF alpha over IL10 and TGF beta and thus shifting the polarization
304 towards M1. Although there is not much increase in fold change of IL12, but if we observe
305 minutely, reciprocity in regulation have been observed between IL10 and IL12 at 45-60 min post
306 infection (Fig 7a & 7c). The major increase in fold change of IFN γ and inducible nitric oxide
307 synthase (iNOS) shows that introduction of designed synthetic circuit is tilting the macrophage
308 phenotype towards classical activation, resulting in killing of parasite inside macrophages (Fig
309 7b).

310

311 **B. Nitrite Estimation**

312 The potential of the designed synthetic circuit was further validated by quantifying nitrite in the
313 system, which is indicative of macrophage polarization towards M1 phenotype. The study is
314 further divided into five groups as mentioned above and Lipophosphosaccharide (LPS) is taken
315 as positive control. Production of nitrite among control, infection and empty vector are found to
316 be similar but when designed synthetic circuit is induced in infected cells, nitrite production is
317 increased which shows that the IL6 synthetic biological circuit is shifting macrophage
318 polarization towards M1 phenotype. With the treatment of miltefosine, nitrate production is
319 further increased (Fig 8c).

320

321 **C. Parasite load assay:**

322 After nitrite estimation, parasite burden have been estimated in various groups (Fig.8a &8b). No
323 change in parasite burden has been observed post 30 minutes of infection either in transfected or
324 non-transfected system. During 45-60 minutes post infection, the fold change in iNOS and IFN γ

325 (fig 7b) have been increased together with high nitrite production (Fig 8c) resulting in significant
326 decrease in parasite load in transfected system (CTI and CTIM).

327

328 **Discussion**

329 IL6 gene expression systems, designed in this study, deal with stochasticity due to the random
330 nature of cellular dynamics associated. The effect of system non-linearity and stochasticity
331 combined with global sensitivity analysis has given sufficient impetus for IL6 synthetic circuit
332 modular analysis which in turn provides framework of retroactivity, all together on a system
333 wide level. The model combined with experimental data captured the host-immune dynamics of
334 parasitic infection and helped identify key components that is crucial for explaining individual
335 variability of different cytokines for a dynamical cellular response. Identification of key
336 components in these complex networks and linking these multivariate interactions to events at
337 different physiological scales, for example, tissue level behavior that directly contributes to
338 disease states, is the crux in systems immunology. During the process of model refinement in
339 this paper, we have identified the ratio of SOCS1:SOCS3as 3:2 for establishment of infection
340 which is further exploited as a target for designed therapeutics. The elevated levels of SOCS1
341 protein (60,000 molecules/ cell) have been mathematically quantified and found to inhibit the
342 signaling of proinflammatory cytokine such as IL12, IFN γ , TNF α . Further this inhibition
343 resulted in increased production of anti-inflammatory cytokines (around 2-7 fold change have
344 been found as compared with control samples). Model analysis at various levels flux, sensitivity
345 and principle component analysis represented the key reactions governing the dynamics of
346 diseased state and SOCS1 playing a crucial role in the same. To add to this, structural analysis of
347 these proteins helped identify specific regions responsible for its inhibitory action. The region is
348 then targeted by designing set of peptides against it. The *in silico* design and analysis of the
349 SOCS1- peptide complex ensures us to test the efficiency in *in vitro* condition. In order to make
350 the delivery of the peptide more specific and less expensive, we opt for synthetic biology
351 approach, wherein, an inducible gene regulatory circuit delivers the designed peptide at specific
352 location (in present work it is in cytoplasm where there is production of SOCS1 protein). Here,
353 the circuit design is precise as well as simple to avoid unnecessary complications during its

354 transfection or else like a Rube Goldberg machine the designed circuit may look exciting *in*
355 *silico* but would rarely yield informative results in wet lab conditions. The confirmatory analysis
356 of the designed therapeutic shows a remarkable upregulation in pro-inflammatory cytokines such
357 as TNF α , iNOS, IFN γ and IL12 and apparently down regulation of anti-inflammatory cytokines
358 IL10 and TGF β . The present data is indicative of the effective functioning of the synthetic
359 circuit. The results have further been confirmed through estimation of nitric oxide as well as
360 parasite load in macrophages.

361 One of the major aspects of this current concept is by using system driven synthetic immunology
362 approach, we have actually targeted the host system (which contribute to disease progression)
363 rather than the parasite itself counteracting the issue of resistance development. The inducible
364 nature of the synthetic circuit ensures the control over the designed product and its action over
365 the host system at cellular level. Robustness/homeostasis of the synthetic circuit corresponds to
366 the circuit capability to stabilize a quantity (e.g., the fluorescence level) against deviations from a
367 given value (the one at steady state, for inference). Homeostasis attained via a designed structural
368 motif/peptide inserted into the circuit helped to establish a temporal program of gene expression.
369 The comparison of the response time at different steps quantified the delay in the output
370 production due to the cascade length, made by a series/row of genes, the first regulating the
371 second one, the second the third one and so on. Each regulation adding a step to the working
372 gene cascade and is not easy to engineer *in vivo* because the noise in the output is amplified at
373 intermediate fluorescence values for high cascade length. This might prevent synchronization of
374 cell response over a population. Moreover, a careful fine-tuning of kinetics is necessary in order
375 to assure proper signal propagation along the IL6 cascade. A negative feedback loop accelerates
376 the response time of IL6 circuit and stabilizes protein concentration. As discussed, the major
377 limitation of the systems comes when the therapy is taken at complex biological level such as
378 tissue/organ or entire organism. At higher biological level, the system design is achieved with
379 respect to the complexity of the biochemical network vis-a-vis combining the present design of
380 the synthetic circuit with CRISPR-Cas9 system for its better performance in *in vivo* system (20).
381 Nonetheless, it will make the system much more bulky which eventually affects its transfection
382 efficiency. Fine tuning of the biological response may pose hindrance at higher level.
383 Nevertheless, it is evident that synthetic biology approach is still among the prominent and most

384 appropriate choice for designing new therapeutics regime because of its specificity, cost
385 efficiency and less off target effects.

386

387 **MATERIALS AND METHODOLOGY:**

388 *In silico:*

389 **A. Reconstruction and Analysis of IL6 Mathematical Model**

390 Data fitting was performed with respect to the ratio of SOCS1/ SOCS3, obtained from
391 wet lab experimentation (Western Blotting) followed by optimization wherein respective
392 parametric changes have been performed to fine tune the models. The entire data sets
393 were simulated with deterministic approach using 15s ODE solver followed by sensitivity
394 analysis which quantifies the dependency of model trajectories upon variation in
395 introduced parameters. Further, quantification of prediction uncertainties has been
396 performed. Model construction, refinement and analysis have been performed in
397 Simbiology Matlab Tool box (v7.11.1.866) and Copasi (v4.19).

398

399 **B. Multi Objective Optimization and Evolvability**

400 The macrophage phenotype network have been optimized by defining two objective
401 function, f (1): SOCS1 associated with anti-inflammatory response, f(2): SOCS3
402 associated with pro-inflammatory response. We have used Multi-objective genetic
403 algorithm (MOGA) to optimize the ratio of SOCS1:SOCS3(21). The optimization was
404 performed in MATLABs' Optimization toolbox (7.11.1.866) (MathWorks Inc.) using the
405 function solver "gamultiobj".

406

407 **C. Target Identification and Protein-Protein Docking**

408 The refined models have further been analyzed and reduced which crucified Suppressor
409 of Cytokine Signaling 1 (SOCS1) as the target. 3D structure prediction have been done
410 for various proteins of IL6 signaling complex (mSOCS1, mgp130, mL6R and mJAK)
411 using *ab initio* modeling techniques (Robetta) and homology modeling (Modeller 9.18)
412 apart from mL6 (PDB ID: 2L3Y). SOCS1 protein was docked with IL6 signaling

413 complex to identify interfacial residues involved in interaction (Fig.5a). Most of the
414 residues belong to SH2 domain of SOCS1 and henceforth non-conserved region around
415 SH2 domain is targeted for peptide designing using Dead End Elimination algorithm. The
416 non-conserved regions were identified through multiple sequence alignment of all the
417 SOCS1 protein of mouse (MultAlign) (Fig.5c).

418 **D. Peptide Design, Docking and MD Simulations**

419 Peptide library was designed using deterministic search method (Dead End Elimination)
420 and secondary structure was obtained through PEPstrMOD(22), followed by docking
421 against SOCS1 through Autodock Vina (v1.5.6)(23) and interaction studies through
422 Ligplot(24). Selected peptide-protein complex was further subjected to molecular
423 dynamic simulations for 30ns to study its stability in physiological condition. MD
424 simulation was performed using DESMOND 3.2 (D.E. Shaw Research) from Maestro 8.2
425 (25), in explicit TIP3P water model using orthorhombic box with a default 10nm cutoff
426 PBC (periodic boundary condition) for a time period of 50ns with the time steps of 2 fs.
427 The RMSD, RMSF and the trajectories were analyzed using simulation event analysis in
428 Desmond 3.2.

429

430 **E. Synthetic Circuit Design and Quasipotential Landscape**

431 Designing and simulation of synthetic circuit was performed in Tinker cell (v1.2.693)
432 (26). Modularity and orthogonality of the circuit was confirmed through BoolNet (27) .
433 Time series data for 100 time units were generated through Gene Regulatory Network
434 Inference using Time Series (GRENITS) (v 1.24.0)(28, 29). Various parts of synthetic
435 circuit were obtained from Registry of Standard Biological Parts (iGEM) (Table 2) and
436 assembled in Snapgene (v3.2.1), followed by its procurement in the form of plasmid from
437 Gene art Thermofisher Scientific. Stability of the synthetic circuit was achieved by
438 obtaining its nullcline state through Berkeley Madonna (Version 9.1.3), followed by
439 obtaining quasipotential landscape through equation $V_q = -((LacR) + (peptide:8)) * DT$
440 derived from the Waddington's epigenetic landscape (30).

441

442

443 ***In vitro:***

444 **A. Cell culture and parasites** - The pathogenic promastigote form of *Leishmania major* strain
445 (MHOM/Su73/5ASKH) were maintained in Roswell Park Memorial Institute (RPMI) 1640 with
446 20 % fetal bovine serum (Sigma) and 50 U/ml penicillin. The parasite was passaged regularly
447 through BALB/c by injecting stationary phase promastigotes in subcutaneous region in order to
448 maintain its virulence (31). The murine macrophage cell line RAW264.7 was maintained at 37
449 °C with 5% CO₂ in Dulbecco's Modified Eagle Medium (DMEM) with 10% fetal bovine serum
450 and penicillin (100ug/ml).

451
452 **B. Reagents, Antibodies, Probes and Constructs** -All other chemicals were from Sigma-
453 Aldrich, unless indicated otherwise. Antibodies for Western blotting such as anti-IL6 (be006)
454 from Biocell, anti-phospho STAT3 (S2690), from Sigma and mouse IL6 (#5210), anti-phospho
455 STAT1 (#9177), anti- SOCS1 (#2923) and anti-SOCS3 (#3950) were obtained from Cell
456 Signaling Technology (CST). Taqman Chemistry was used to perform and quantify cytokine
457 expression levels in samples. Mouse specific taqman probes (4331182) and Mastermix
458 (4304437) were obtained from ThermoFisher Scientific. Peptidoglycan from *Staphylococcus*
459 *aureus* (PGN-SA) (#tlrl-pgns2) and Mab-mTLR2 (#mab-mtlr2) from InvivoGEN were procured.
460 Designed synthetic circuit was procured in the form of plasmid from GeneArt, ThermoFisher
461 Scientific.

462
463 **C. Macrophage and Parasite infection** :For *in vitro* experimentation, RAW 264.7 cell line was
464 infected with stationary phase promastigotes in 1:10 macrophage/ parasite ratio for 24 hrs,
465 followed by washing of un-internalized parasite and incubating the infected cells in DMEM with
466 10% FBS.

467
468 **D. Transfection of macrophages:**
469 Macrophages were transfected with designed synthetic construct (plasmid form) using
470 Polyethylenimine transfection reagent in a 3:1 ratio of PEI to DNA (w/w). The transfected cells
471 were induced by 1mM IPTG (Isopropyl β- d-1-thiogalactopyranoside) for 48 hrs followed by

472 infection. Transfected cells were visualized for GFP expression on EVOS FL fluorescence
473 microscope.

474 **E. mRNA isolation, RT PCR and Real time PCR**

475 For cytokine profiling, after washing un-internalized parasite, cells were lysed and total RNA
476 was isolated at 0 min, 15min, 30 min, 45 min and 60 min post-infection. The total RNA was
477 isolated using TRI Reagent as per the manufacturer's instructions. The cDNA synthesis was
478 done using 2ug of total RNA through high Capacity cDNA kit (Invitrogen) as per the
479 manufacturer's instructions.

480 Q-PCR was performed on StepOnePlus Real-Time PCR System (Thermo Scientific). For each
481 reaction, 5ul Taqman Master mix (Invitrogen), 1ug cDNA as Template, 0.5 ug Taqman probes
482 (**S6**) was taken, and the reactions were performed on thin-wall 0.1 ml fast 96 well plate (Applied
483 Biosystems) for a total of 10 ul reaction mix. Relative quantitation was done using the
484 comparative threshold ($\Delta\Delta CT$) method. The mRNA expression levels of the target genes were
485 normalized against those of β actin levels and expressed as relative fold change compared with
486 untreated controls.

487

488 **F. Western Blotting**

489 **Cross talk validation:** For activation, RAW 264.7 cell line was treated with TLR2 activator
490 PGN-SA (Peptidoglycan of *Saccharomyces aureus*) for 24 hours and for inhibition, culture was
491 treated with 2ug/ml of mTLR2 before activation. The activation of IL6 pathway has been
492 performed by treating cell with mIL6 (50ng/ml) for 24hrs and for inhibition, anti-IL6 antibody
493 (1ug/ml) treatment was given for 1 hour prior IL6 treatment.

494 **SOCS1/SOCS3 validation:** The macrophage derived cell line RAW 264.7 cell line were
495 infected with promastigote form of parasite in 1: 10 ratio, followed by 24hrs incubation and
496 removal of undigested parasite. The culture was then treated with 50ng/ml of mouse IL6 protein
497 for another 1 hour followed by sample collection.

498 For Western blotting, cells were treated with indicated reagents and lysed with lysis buffer (50
499 mM Tris [pH 7.5], 250 mM NaCl, 50mM NaF, 10% glycerol, 5 mM EDTA, 0.5 mM Sodium
500 orthovanadate, and 0.5% TritonX), and a protease inhibitor mixture, by incubation on ice for 20
501 min followed by centrifugation of lysates (15,000 rpm, at 4°C for 20 min), and supernatants were

502 quantified by Bicinchoninic acid kit (Thermofisher scientific). Equal amount of protein was
503 loaded on SDS-PAGE, and resolved proteins were transferred to nitrocellulose membrane
504 (Millipore, Billerica, MA) and blocked with 3% Bovine serum albumin in TBST (20 mM Tris
505 [pH 7.5], 150 mM NaCl, and 0.1% Tween 20). Membranes were incubated with primary
506 Antibody (1:1000 dilution) at 4°C overnight, followed by washing with TBST, and incubated
507 with HRP-conjugated secondary Ab. Immuno-reactive bands were visualized with the Luminol
508 reagent (Santa Cruz Biotechnology, Santa Cruz, CA). Densitometric analysis of bands was
509 performed using Image J software.

510

511 **G. Parasite load assay**

512 After specific treatment, macrophages were washed with 1X cold PBS followed by fixation in
513 4% paraformaldehyde (PFA), and permeabilization in 0.1% Triton X. Then the cells were stained
514 with DAPI (1µg/ml). Parasites per macrophage were calculated using EVOS FL fluorescence
515 microscope and they were presented in terms of infectivity index (percentage of infected cells x
516 number of parasites per infected cells).

517

518 **H. Estimation of ROS production**

519 Presence of Nitrite in culture media is an indicator of Nitric oxide production by cells (precisely
520 macrophage polarization towards M1 phenotype). The Cell culture supernatant in 150 µl volume
521 is treated with 20 µl of Griess reagent (0.1% N-(1-naphthyl)ethylenediamine and 1% sulfanilic
522 acid in equal volume; Thermofisher Scientific) to set a total volume of 300 µl per reaction and
523 incubated for 10 minutes at room temperature followed by colorimetric estimation at 540nm on.

524 **I. Animal Maintenance:** Female BALB/c mice, 6–8 weeks old with 18–20 g weight, originally
525 procured from The Jackson Laboratory (Bar Harbor, ME) and maintained in the Experimental
526 Animal Facility of National Centre for Cell Science (NCCS), Pune. Animals were used
527 according to the Institutional Animal Ethical Committee–approved animal use protocol (IAEC
528 Project Number-IAEC/2016/B-269).

529 **J. Statistical analysis:** The *in-vitro* experiments were performed in triplicates. The error bars are
530 represented as mean \pm s.d. The statistical significance between the indicated experimental and

531 control groups was deduced by using Student's *t*-test and One way ANOVA (with Tukey's
532 correction).

533 **Figures**

534 **Fig.1** Graphical representation of Systems and Synthetic immunology

535 **Fig. 2** Refinement of mathematical model: (a) Mathematical model of M1 phenotype depicting higher
536 production of iNOS and SOCS3, (b) Mathematical model of M2 phenotype representing higher
537 production of Anti-inflammatory factors (AIF) and SOCS1 at the end of 80 time unit simulation. (c)
538 Comparative flux analysis representing reactions with higher flux. (d) Principle component analysis of
539 DSM model showing key components governing the system. (e) Quantification of SOCS1/SOCS3
540 concentration ratio obtained after simulation of mathematical model. (f) Further, macrophages were
541 exposed to stationary phase promastigotes in ratio of 1: 10 (macrophage: parasite) for 24 hrs and un-
542 internalized parasite was washed followed by treatment of IL6 (50ng/ml) for 1 hour post infection. Ratio
543 was further quantified through western blotting followed by densitometric analysis of the blots against b
544 actin level. (g) Quantification of IL6 cytokine has been done post one hour of *L. major* infection through
545 western blotting. For all western blot experiments, equal amount of protein was resolved and blotted for
546 b-actin to ensure equal loading. The experiments were performed thrice. Results from one representative
547 experiment are shown. The densitometric value represents mean \pm SD with p value *p < 0.05, **p < 0.01,
548 ***p < 0.001.

550 **Fig. 3** Identification of cross talks between TLR2/TLR6-IL6 signaling pathways (a) Degree distribution
551 of cross talks identified through network analysis (b) Western blotting was used to check expression
552 levels of phosphorylated STAT1 (S727) and STAT3 (Y705) during activation of one pathway &
553 inhibition of another pathway and vice versa. (c) & (d) Expression levels of phosphorylated STAT1
554 (S727) and STAT3 (Y705) during activation and inhibition of their respective pathway. For all western
555 blot experiment, equal amount of protein was resolved and blotted for b-actin to ensure the equal loading.
556 The experiments were performed thrice. Results from one representative experiment are shown.

558 **Fig.4** Multi objective genetic algorithm for optimization of SOCS1 /SOCS3 ratio (a) Graph of elite
559 population (b) Graph showing average distance between individuals indicating the decreased mutation
560 rate (c) Pareto front between two objective function representing non dominated solution (d) Graph
561 depicting the average spread measure of the solution.

563 **Fig.5** Peptide designed against SOCS1 protein: (a) Protein- protein docking of IL6-IL6R-gp130 complex
564 with JAK1 and SOCS1 to identify interfacial residue during interaction. (BioLuminate Package,
565 Schrödinger Release 2017-3 Suites). (b &c) Multiple sequence alignment identified non-conserved
566 regions near SH2 domain of SOCS1 protein as a target for peptide design. (d) The complex shows that
567 peptide 8 has been docked at desired region near SH2 domain that may inhibit the interaction of SOCS1

568 and gp130 (Autodock v1.5.6) (e) Interaction plot of SOCS1 and Peptide8 amino acid residues (Ligplot+).
569 (C) Molecular dynamics simulation of SOCS1-peptide 8 complexes have been performed for 30ns
570 depicting RMSD plot with stabilized fluctuations, indicating the stability of the SOCS1-Peptide 8
571 complex.

572

573 **Fig. 6** Synthetic circuit Design: (a) Modular arrangements of biological parts to receive an output in
574 Tinker Cell (b) After simulating the system, the output is received in the form of oscillatory behavior of
575 LACR, Peptide8 and GFP. (c) Nullcline form of synthetic circuit with states depicting synthetic circuit
576 reaching its equilibrium state. (d) Convergence of statistical variables signifies the stability of the system.
577 (e) Wiring of the circuit signifies the major regulatory axis as Lac Repressor gene. (f) Attractor states of
578 synthetic circuits shows its ON and OFF stage (g) Plasmid map of designed synthetic circuit. Plasmid was
579 transfected and expressed in RAW264.7 cell line, through IPTG induction, followed by DAPI staining
580 showing (h) OFF stage of the system *in vitro* (no IPTG induction) (i) ON stage of the system *in vitro*
581 (with IPTG induction).

582

583

584 **Fig.7** Cytokine profiling of *in vitro* validation of synthetic circuit: Macrophages were first transfected
585 with synthetic circuit using, Polyethylenimine (3:1 ratio PEI: DNA) and then induced with 1mM IPTG
586 for 48 hrs followed by infection with stationary phase promastigotes in 1:10 macrophage to parasite ratio
587 for 24 hrs. Un-internalized parasites were washed off and samples were collected at different time points.
588 (a) Cytokines released during initial interaction (b) Cytokines associated with M1 phenotype. The levels
589 of IFN γ and iNOS has not been observed in Infection group therefore, bars are not shown. (c) Cytokines
590 associated with M2 phenotype. The experiments were performed thrice. The error bars represents mean \pm
591 SD with p value *p < 0.05, **p < 0.01, ***p < 0.001

592

593 **Fig.8** *In vitro* validation of designed synthetic circuit: (a) Estimation of parasite burden in terms of
594 infectivity index in various infected and transfected groups. (b) The percentage of macrophage infected
595 with *L. major* parasite (c) Nitrite estimation for various groups post one hour of infection in comparison
596 with LPS treatment. (d) Transmitted microscopic image (100X) of control and infected RAW264.7
597 macrophage. The experiments were performed three times. One way ANOVA (with Tukey's correction)
598 have been used to perform statistical analysis of Infectivity index and student t test have been used to
599 analyse Nitric oxide estimation The error bars represents mean \pm SD with p value *p < 0.05, **p < 0.01,
600 ***p < 0.001.

601

602 **Tables**

603 Table 1: Reaction that governs the disease progression at cellular level

604 Table 2: Registry of standard biological parts with parts registry number (**Sequences of the same**
605 **enlisted in S7)**

606 **Supplemental Material**

607 **S1:** Concentration of components of mathematical model

608 **S2A-S2B:**

609 S2A: Peptide sequences and Docking Score

610 S2B: Characteristic of Peptide8 obtained from ExPASy ProtParam tool

611 **S3A-S3B:**

612 S3A: RMSF Plot of SOCS1-P8 Complex

613 S3B: Physical parameters during 30ns MD simulation

614 **S4:** DNA sequence of parts used in the synthetic circuit

615 **S5:** Insert Verification details

616 **S6:** Invitrogen® Assay ID for RT PCR probes.

617 **S7:** Raw Images of Western Blots

618

619

620 **Acknowledgements**

621 Bhavnita Soni acknowledges her Senior Research fellowship from INSPIRE, Department of
622 Science and Technology (DST), Ministry of Science and Technology, Government of India.

623 Authors would like to thank Cell Repository and Media Section of National Centre for Cell
624 Science (NCCS). We also extend our thanks to the Director, NCCS for supporting
625 Bioinformatics and High Performance Computing Facility (BHPCF) at NCCS, Pune, India.

626

627 **Conflict of Interest**

628 Authors potentially declare no conflict of interest.

629

630 **REFERENCES:**

631 1. Croker BA, Kiu H, Nicholson SE. 2008. SOCS regulation of the JAK/STAT signalling
632 pathway. *Semin Cell Dev Biol*.


633 2. Duncan SA, Baganizi DR, Sahu R, Singh SR, Dennis VA. 2017. SOCS proteins as
634 regulators of inflammatory responses induced by bacterial infections: A review. *Front*
635 *Microbiol* 8:1–15.

636 3. Sun K, Salmon S, Yajjala VK, Bauer C, Metzger DW. 2014. Expression of Suppressor of
637 Cytokine Signaling 1 (SOCS1) Impairs Viral Clearance and Exacerbates Lung Injury
638 during Influenza Infection. *PLoS Pathog*.


- 639 4. Chien H, Alston CI, Dix RD. 2018. Suppressor of Cytokine Signaling 1 (SOCS1) and
640 SOCS3 Are Stimulated within the Eye during Experimental Murine Cytomegalovirus
641 Retinitis in Mice with Retrovirus-Induced Immunosuppression. *J Virol* 92.
- 642 5. Chandrakar P, Parmar N, Descoteaux A, Kar S. 2020. Differential Induction of SOCS
643 Isoforms by *Leishmania donovani* Impairs Macrophage–T Cell Cross-Talk and Host
644 Defense . *J Immunol*.
- 645 6. Soni B, Saha B, Singh S. 2018. Systems cues governing IL6 signaling in leishmaniasis.
646 Cytokine.
- 647 7. Yang L, Ebrahim A, Lloyd CJ, Saunders MA, Palsson BO. 2019. DynamicME: Dynamic
648 simulation and refinement of integrated models of metabolism and protein expression.
649 *BMC Syst Biol*.
- 650 8. Hahl SK, Kremling A. 2016. A comparison of deterministic and stochastic modeling
651 approaches for biochemical reaction systems: On fixed points, means, and modes. *Front*
652 *Genet*.
- 653 9. Shain KH, Yarde DN, Meads MB, Huang M, Jove R, Hazlehurst LA, Dalton WS. 2009.
654 β 1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells:
655 Implications for microenvironment influence on tumor survival and proliferation. *Cancer*
656 *Res*.
- 657 10. Fisher DT, Appenheimer MM, Evans SS. 2014. The two faces of IL-6 in the tumor
658 microenvironment. *Semin Immunol*.
- 659 11. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. 2001. C-reactive protein,
660 interleukin 6, and risk of developing type 2 diabetes mellitus. *J Am Med Assoc*.
- 661 12. Smole A, Lainšček D, Bezeljak U, Horvat S, Jerala R. 2017. A Synthetic Mammalian
662 Therapeutic Gene Circuit for Sensing and Suppressing Inflammation. *Mol Ther*.
- 663 13. Ye H, Xie M, Xue S, Hamri GC El, Yin J, Zulewski H, Fussenegger M. 2017. Self-
664 adjusting synthetic gene circuit for correcting insulin resistance. *Nat Biomed Eng*.
- 665 14. Kis Z, Pereira HSA, Homma T, Pedrigi RM, Krams R. 2015. Mammalian synthetic
666 biology: Emerging medical applications. *J R Soc Interface*.
- 667 15. Ye H, Fussenegger M. 2014. Synthetic therapeutic gene circuits in mammalian cells.
668 *FEBS Lett*.

- 669 16. Wroblewska L, Kitada T, Endo K, Siciliano V, Stillo B, Saito H, Weiss R. 2015.
670 Mammalian synthetic circuits with RNA binding proteins for RNA-only delivery. *Nat*
671 *Biotechnol.*
- 672 17. Perry N, Ninfa AJ. 2012. Synthetic networks: Oscillators and toggle switches for
673 *escherichia coli*. *Methods Mol Biol.*
- 674 18. Elowitz MB, Leibier S. 2000. A synthetic oscillatory network of transcriptional regulators.
675 *Nature.*
- 676 19. de Veer MJ, Curtis JM, Baldwin TM, DiDonato JA, Sexton A, McConville MJ, Handman
677 E, Schofield L. 2003. MyD88 is essential for clearance of *Leishmania major*: Possible role
678 for lipophosphoglycan and Toll-like receptor 2 signaling. *Eur J Immunol.*
- 679 20. Xu X, Qi LS. 2019. A CRISPR–dCas Toolbox for Genetic Engineering and Synthetic
680 Biology. *J Mol Biol.*
- 681 21. Deb K, Pratap A, Agarwal S, Meyarivan T. 2002. A fast and elitist multiobjective genetic
682 algorithm: NSGA-II. *IEEE Trans Evol Comput.*
- 683 22. Singh S, Singh H, Tuknait A, Chaudhary K, Singh B, Kumaran S, Raghava GPS. 2015.
684 PEPstrMOD: Structure prediction of peptides containing natural, non-natural and
685 modified residues. *Biol Direct.*
- 686 23. Trott oleg, Arthur J. Olson. 2010. AutoDock Vina: Improving the Speed and Accuracy of
687 Docking with a New Scoring Function, Efficient Optimization, and Multithreading. *J*
688 *Comput Chem.*
- 689 24. Wallace AC, Laskowski RA, Thornton JM. 1995. Ligplot: A program to generate
690 schematic diagrams of protein-ligand interactions. *Protein Eng Des Sel.*
- 691 25. Bowers KJ, Chow E, Xu H, Dror RO, Eastwood MP, Gregersen BA, Klepeis JL,
692 Kolossvary I, Moraes MA, Sacerdoti FD, Salmon JK, Shan Y, Shaw DE. 2006. Scalable
693 algorithms for molecular dynamics simulations on commodity clusters *Proceedings of the*
694 *2006 ACM/IEEE Conference on Supercomputing, SC'06.*
- 695 26. Chandran D, Bergmann FT, Sauro HM. 2009. TinkerCell: Modular CAD tool for
696 synthetic biology. *J Biol Eng.*
- 697 27. Müssel C, Hopfensitz M, Kestler HA. 2010. BoolNet-an R package for generation,
698 reconstruction and analysis of Boolean networks. *Bioinformatics.*


- 699 28. Morrissey ER, Juárez MA, Denby KJ, Burroughs NJ, Ideker T. 2011. On reverse
700 engineering of gene interaction networks using time course data with repeated
701 measurements *Bioinformatics*.
- 702 29. Morrissey E. 2012. GRENITS: Gene Regulatory Network Inference Using Time Series. R
703 package version 1.24.0. 1–5.
- 704 30. Bhattacharya S, Zhang Q, Andersen ME. 2011. A deterministic map of Waddington’s
705 epigenetic landscape for cell fate specification. *BMC Syst Biol*.
- 706 31. Kébaïer C, Louzir H, Chenik M, Ben Salah A, Dellagi K. 2001. Heterogeneity of wild
707 *Leishmania major* isolates in experimental murine pathogenicity and specific immune
708 response. *Infect Immun*.
- 709
- 710
- 711
- 712
- 713
- 714
- 715
- 716
- 717
- 718




SYSTEMS IMMUNOLOGY




SYNTHETIC IMMUNOLOGY




APPLICATION



(a)



(b)




(c)




(d)

| MODELS | SOCS1 (MOLECULES/ CELL) | SOCS3 (MOLECULES/ CELL) | SOCS1:SOCS3 |
|--|-------------------------------|-------------------------------|-------------|
| DISEASED STATE MODEL (M2 PHENOTYPE) | 60,000 | 40,000 | 1:2 |
| HEALTHY STATE MODEL (M1 PHENOTYPE) | 25000 | 60,000 | 1:4 |

(e)




(f)




(g)


Degree Distribution




(a)




(b)




(c)




(d)




(a)




(b)



(c)



(d)




(a)




(b)




(c)












(d)



(e)






(f)






(h)



(i)




(a)




(b)




(c)




(a)



(b)



(c)



(d)